中文(繁體)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients

只有註冊用戶可以翻譯文章
登陸註冊
鏈接已保存到剪貼板
狀態已完成
贊助商
Wolnei Caumo

關鍵詞

抽象

In this phase II, randomized, double-blind clinical trial, the investigators intended to evaluate the home-based effect of transcranial direct current stimulation (tDCS) in patients with fibromyalgia. This syndrome affects between 3-5% of the population in an age group 40-60 years also occurring in childhood and old age. Reaches 3.4% of women and 0.5% of men. Fibromyalgia is a chronic widespread pain syndrome in various parts of the body. The neuromodulation techniques have as a principle produce inhibition or cortical arousal. The tDCS is a non-invasive brain stimulation method used to modulate the cortical excitability, using a low intensity direct current (1-2mA) directed to the scalp via the cathode and anode electrodes. The current reaches the cortex, producing hyperpolarization or depolarization of the axonal membrane potential. Evidence has shown that this method is presented as a technique able to alter cortical and subcortical neural networks. This technique has been used to treat psychiatric disorders such as depression, acute mania, bipolar affective disorder, panic, hallucinations, obsessive compulsive disorder, schizophrenia, withdrawal, rehabilitation after stroke, pain syndromes such as neuropathic pain, migraine, pancreatitis pain chronic and fibromyalgia. The tDCS is a low cost technique, with virtually no side effects and which exerts therapeutic effect by neuromodulatory pathways by distinct pathways activated by the drugs. In this scenario falls within the importance of developing this device for home use by fibromyalgia patients, since it is easy to use and thereby enables maintaining the benefit observed in studies performed and supervised frequently used in care centers. The use of tDCS over the long term is not feasible in hospital by patients demands, sometimes every day or more than once a week, removing the patient from their activities, and cost shifting and overload the healthcare system. Therefore, the objective of this study is to evaluate the effect of home-based tDCS in fibromyalgia patients in long-term treatment.

描述

Will be included women aged between 18 and 65 years, chronic pain fibromyalgia according to the criteria of the American College of Rheumatology, pain unresponsive to analgesics such as paracetamol, acetylsalicylic acid, ibuprofen, Carisoprodol, Zanaflex (Tizanidine) and Codeine. And give informed consent to participate after initial evaluation. Primary outcome is to evaluate the effect of treatment with home-base tDCS in patients with fibromyalgia. Secondary outcomes are: compare the effect of active home-based tDCS and sham in cortical neurophysiological processes and subcortical to stimulation with TMS and standardized noxious stimuli with and without concomitant conditioned Pain Modulation (CPM) in pain threshold outcomes to the test mechanical pressure, heat-algesic stimulus, cortical excitability parameters [evoked rest motor (MEP) MEP enough to evoke amplitude of 1 mV peak to peak, silent period (SP), motor threshold (MT), variation in blood volume and oxygenation cortical motor area [oxy-hemoglobin concentrations (Hbo) / deoxy-hemoglobin (HBr)] optically functional neuroimaging (NIRS) and variation in the frequency of alpha and beta waves of motor area stimulated by tDCS assessed by electroencephalogram (EEG). In surrogate outcome, the investigators will compare the effect of active home-sham tDCS the tDCS in pain levels and functional capacity, catastrophic thinking, bookmark levels of neurotrophic activity (BDNF) and astrocytic (S100 beta).

日期

最後驗證: 07/31/2018
首次提交: 10/27/2015
提交的預估入學人數: 01/10/2016
首次發布: 01/11/2016
上次提交的更新: 07/31/2018
最近更新發布: 08/02/2018
實際學習開始日期: 12/31/2015
預計主要完成日期: 04/30/2018
預計完成日期: 06/11/2018

狀況或疾病

Fibromyalgia

干預/治療

Other: Active-tDCs

Other: Sham-tDCS

-

手臂組

干預/治療
Active Comparator: Active-tDCs
17 patients will receive Active-tDCS intervention (2mA, 30 min) at home.
Other: Active-tDCs
Active home-based tDCS applied at home.
Sham Comparator: Sham-tDCS
17 patients will receive Sham-tDCS intervention (2mA, 30 min) at home.
Other: Sham-tDCS
Sham home-based tDCS applied at home.

資格標準

有資格學習的年齡 18 Years 至 18 Years
有資格學習的性別Female
接受健康志願者
標準

Inclusion Criteria:

- have chronic pain fibromyalgia according to the criteria of the American College of Rheumatology

- Pain unresponsive to analgesics such as paracetamol, acetyl salicylic acid, Ibuprofen, Carisoprodol, Zanaflex (Tizanidine) and Codeine

- Give informed consent to participate after initial evaluation.

Exclusion Criteria:

- Pregnancy

- Treatment with carbamazepine and gabapentin

- The. Metallic implant in the brain

- Medical devices implanted in the brain

- Alcohol or drug abuse history in the last 6 months

- Suffering from severe depression (with score> 30 on the Beck Depression Inventory)

- History of neurological disorders

- Unexplained fainting History

- History of head trauma or momentary loss of consciousness (self reported)

- Neurosurgery History

- Decompensated systemic diseases, and chronic inflammatory diseases (lupus, rheumatoid arthritis, renal failure and hepatitis).

結果

主要結果指標

1. Pain level in fibromyalgia patients using home-based tDCS [Ffive days per week, during 12 weeks.]

Evaluate the level of pain in fibromyalgia patients before and after each home-based tDCS session. We will use numerical pain scale to do that.

次要成果指標

1. Serum levels of Brain Derived Neurotrophic Factor (BDNF) [2 days]

Measurement of serum levels of BDNF pre and pos application of home-based application of home-based tDCS

2. Serum levels of calcium-binding protein B (S100B) [2 days]

Measurement of serum levels of S100B pre and pos application of home-based tDCS

3. Functional capacity [2 days]

Measurement of functional capacity pre and pos application of home-based tDCS with functional capacity scale in chronic pain.

4. Catastrophic thinking [2 days]

Measurement of catastrophic thinking pre and pos application of home-based tDCS with catastrophizing scale.

加入我們的臉書專頁

科學支持的最完整的草藥數據庫

  • 支持55種語言
  • 科學支持的草藥療法
  • 通過圖像識別草藥
  • 交互式GPS地圖-在位置標記草藥(即將推出)
  • 閱讀與您的搜索相關的科學出版物
  • 通過藥效搜索藥草
  • 組織您的興趣並及時了解新聞研究,臨床試驗和專利

輸入症狀或疾病,並閱讀可能有用的草藥,輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究

Google Play badgeApp Store badge